Conducting Value for Money Analyses for Non-randomised Interventional Studies Including Service Evaluations: An Educational Review with Recommendations.


Journal

PharmacoEconomics
ISSN: 1179-2027
Titre abrégé: Pharmacoeconomics
Pays: New Zealand
ID NLM: 9212404

Informations de publication

Date de publication:
07 2020
Historique:
pubmed: 16 4 2020
medline: 29 5 2021
entrez: 16 4 2020
Statut: ppublish

Résumé

This article provides an educational review covering the consideration of conducting 'value for money' analyses as part of non-randomised study designs including service evaluations. These evaluations represent a vehicle for producing evidence such as value for money of a care intervention or service delivery model. Decision makers including charities and local and national governing bodies often rely on evidence from non-randomised data and service evaluations to inform their resource allocation decision-making. However, as randomised data obtained from randomised controlled trials are considered the 'gold standard' for assessing causation, the use of this alternative vehicle for producing an evidence base requires careful consideration. We refer to value for money analyses, but reflect on methods associated with economic evaluations as a form of analysis used to inform resource allocation decision-making alongside a finite budget. Not all forms of value for money analysis are considered a full economic evaluation with implications for the information provided to decision makers. The type of value for money analysis to be conducted requires considerations such as the outcome(s) of interest, study design, statistical methods to control for confounding and bias, and how to quantify and describe uncertainty and opportunity costs to decision makers in any resulting value for money estimates. Service evaluations as vehicles for producing evidence present different challenges to analysts than what is commonly associated with research, randomised controlled trials and health technology appraisals, requiring specific study design and analytic considerations. This educational review describes and discusses these considerations, as overlooking them could affect the information provided to decision makers who may make an 'ill-informed' decision based on 'poor' or 'inaccurate' information with long-term implications. We make direct comparisons between randomised controlled trials relative to non-randomised data as vehicles for assessing causation; given 'gold standard' randomised controlled trials have limitations. Although we use UK-based decision makers as examples, we reflect on the needs of decision makers internationally for evidence-based decision-making specific to resource allocation. We make recommendations based on the experiences of the authors in the UK, reflecting on the wide variety of methods available, used as documented in the empirical literature. These methods may not have been fully considered relevant to non-randomised study designs and/or service evaluations, but could improve and aid the analysis conducted to inform the relevant value for money decision problem.

Identifiants

pubmed: 32291596
doi: 10.1007/s40273-020-00907-5
pii: 10.1007/s40273-020-00907-5
pmc: PMC7319287
doi:

Types de publication

Comparative Study Journal Article Research Support, Non-U.S. Gov't Review

Langues

eng

Pagination

665-681

Subventions

Organisme : Department of Health
ID : NIHR200166
Pays : United Kingdom

Références

Pharmacoeconomics. 2014 Jul;32(7):613-5
pubmed: 24811892
Health Econ Policy Law. 2016 Oct;11(4):415-32
pubmed: 26906561
Value Health. 2016 Mar-Apr;19(2):138-44
pubmed: 27021746
Pharmacoeconomics. 2008;26(9):733-44
pubmed: 18767894
Pharmacoeconomics. 2020 Mar;38(3):247-257
pubmed: 31930460
Value Health. 2013 Mar-Apr;16(2):231-50
pubmed: 23538175
J Med Ethics. 2007 Nov;33(11):651-4
pubmed: 17971468
Med Decis Making. 2014 Apr;34(3):311-26
pubmed: 24246566
BMJ Glob Health. 2018 Nov 5;3(6):e000964
pubmed: 30483412
Pharmacoeconomics. 2017 Dec;35(Suppl 1):11-19
pubmed: 29052162
Pharmacoeconomics. 2017 May;35(5):561-573
pubmed: 28110382
Pharmacoeconomics. 2005;23(12):1229-42
pubmed: 16336017
Clinicoecon Outcomes Res. 2012;4:145-55
pubmed: 22719214
Med Decis Making. 2016 Jan;36(1):8-19
pubmed: 25908564
Int J Environ Res Public Health. 2018 Nov 05;15(11):
pubmed: 30400563
Eur J Health Econ. 2007 Jun;8(2):111-21
pubmed: 17347844
Arch Dis Child. 2005 Aug;90(8):837-40
pubmed: 16040884
Soc Sci Med. 2019 Jan;220:353-361
pubmed: 30513485
Health Technol Assess. 2018 Mar;22(11):1-204
pubmed: 29516853
Appl Health Econ Health Policy. 2019 Jun;17(3):295-313
pubmed: 30945127
BMJ. 2017 Mar 22;356:j1402
pubmed: 28330879
Clin Med (Lond). 2016 Dec;16(6):501-502
pubmed: 27927810
Ann Intern Med. 2012 Jan 3;156(1 Pt 1):37-40
pubmed: 22213493
Health Policy. 2009 Dec;93(2-3):85-92
pubmed: 19709773
Value Health. 2020 Mar;23(3):277-286
pubmed: 32197720
Am J Med. 1982 Feb;72(2):233-40
pubmed: 7058834
Health Technol Assess. 2011 May;15(22):1-82, iii-iv
pubmed: 21561569
Appl Health Econ Health Policy. 2014 Feb;12(1):7-18
pubmed: 24399360
Appl Health Econ Health Policy. 2019 Oct;17(5):577-590
pubmed: 31098947
Health Res Policy Syst. 2018 Mar 14;16(1):23
pubmed: 29540216
Pharmacoeconomics. 2013 May;31(5):369-73; discussion 375-6
pubmed: 23595557
Pharmacoeconomics. 2019 Feb;37(2):119-130
pubmed: 30474803
Health Econ. 2006 Jul;15(7):677-87
pubmed: 16491461
Int J Technol Assess Health Care. 2019;35(5):367-372
pubmed: 31530332
Value Health. 2018 Mar;21(3):258-265
pubmed: 29566831
BMJ Open. 2019 Nov 21;9(11):e029830
pubmed: 31753870
Eur J Health Econ. 2009 Oct;10(4):357-9
pubmed: 19618224
Int J Epidemiol. 2017 Feb 1;46(1):348-355
pubmed: 27283160
BMC Med Res Methodol. 2019 Jan 9;19(1):8
pubmed: 30626337
Int J Technol Assess Health Care. 2018 Jan;34(5):434-441
pubmed: 30326982
Health Econ. 2001 Mar;10(2):179-84
pubmed: 11252048
Age Ageing. 2019 Dec 1;49(1):57-66
pubmed: 31711110
J Clin Oncol. 2016 Mar 10;34(8):772-3
pubmed: 26786920
Health Policy Plan. 2018 Apr 1;33(3):456-463
pubmed: 29309581
Health Promot Int. 2013 Sep;28(3):281-4
pubmed: 23929877
Health Econ. 2015 Jun;24(6):742-54
pubmed: 24798212
Pharmacoeconomics. 2016 Oct;34(10):981-92
pubmed: 27278217
Age Ageing. 2014 Sep;43(5):703-7
pubmed: 25059421
Pharmacoeconomics. 2014 Apr;32(4):345-65
pubmed: 24504851
BMC Public Health. 2013 Oct 24;13:1001
pubmed: 24153037
Pharmacogenomics. 2013 Nov;14(15):1833-47
pubmed: 24236483
PLoS Med. 2017 Oct 2;14(10):e1002397
pubmed: 28968399
Health Policy. 2009 Mar;89(3):261-70
pubmed: 18657336
Neuropsychiatr Dis Treat. 2016 Jun 10;12:1341-9
pubmed: 27354804
Arch Dis Child. 2005 Aug;90(8):840-4
pubmed: 16040885
BMJ. 2016 Sep 27;354:i5090
pubmed: 27677636
Value Health. 2016 Jan;19(1):1-13
pubmed: 26797229
Pharmacoeconomics. 2012 Nov 1;30(11):981-9
pubmed: 22946789
N Engl J Med. 2016 Jun 2;374(22):2175-81
pubmed: 27248626
BMJ. 2018 Dec 13;363:k5094
pubmed: 30545967
Value Health. 2009 Mar;12 Suppl 1:S27-30
pubmed: 19250128
Health Econ Rev. 2013 Sep 19;3(1):21
pubmed: 24229445
Med Decis Making. 2017 Oct;37(7):747-758
pubmed: 28410564
JAMA. 2013 Nov 27;310(20):2191-4
pubmed: 24141714
Med Decis Making. 2015 Jul;35(5):570-83
pubmed: 25810269
Int J Epidemiol. 2006 Apr;35(2):337-44
pubmed: 16368725
N Engl J Med. 2000 Jun 22;342(25):1887-92
pubmed: 10861325
Pharmacoeconomics. 1998 Mar;13(3):277-88
pubmed: 10178653
J Clin Epidemiol. 2009 May;62(5):499-505
pubmed: 19348976
Pharmacoeconomics. 2015 Apr;33(4):355-66
pubmed: 25595871
Health Technol Assess. 2008 Apr;12(7):iii, ix-x, 1-175
pubmed: 18373906
Value Health. 2018 Mar;21(3):266-275
pubmed: 29566832
Health Policy. 2008 May;86(2-3):129-41
pubmed: 18192059
Pharmacoeconomics. 2019 May;37(5):631-643
pubmed: 30746613
Evaluation (Lond). 2016 Jul;22(3):323-341
pubmed: 27478402
J Clin Epidemiol. 2009 Dec;62(12):1248-52
pubmed: 19364636
Med Decis Making. 2020 Feb;40(2):170-182
pubmed: 32065026
Value Health. 2014 Jan-Feb;17(1):5-14
pubmed: 24438712
Health Technol Assess. 2015 Feb;19(14):1-503, v-vi
pubmed: 25692211
Pharmacoeconomics. 2015 Feb;33(2):105-21
pubmed: 25336432
N Engl J Med. 2017 Aug 3;377(5):465-475
pubmed: 28767357
Emerg Med J. 2015 Jul;32(7):507-8
pubmed: 25820301
Circulation. 2016 Nov 15;134(20):1568-1578
pubmed: 27840334
Appl Health Econ Health Policy. 2015 Dec;13(6):557-65
pubmed: 26324402
Implement Sci. 2014 Dec 18;9:168
pubmed: 25518730
JAMA. 2007 Jul 11;298(2):221-4
pubmed: 17622605
Soc Sci Med. 1989;28(4):299-308
pubmed: 2649989
J Am Stat Assoc. 2019 Apr 30;114(528):1436-1449
pubmed: 32165869
Value Health. 2019 Jan;22(1):13-20
pubmed: 30661627
BMJ. 2019 Oct 23;367:l5657
pubmed: 31645336
J Epidemiol Community Health. 2017 Aug;71(8):827-834
pubmed: 28356325
Am J Prev Med. 2016 Nov;51(5):852-860
pubmed: 27745685
J Clin Epidemiol. 2019 Jan;105:50-59
pubmed: 30236484
Value Health. 2007 Jul-Aug;10(4):305-16
pubmed: 17645685
Health Technol Assess. 1999;3(2):1-134
pubmed: 10448202
Value Health. 2009 Jun;12(4):402-4
pubmed: 19138306
Lancet. 2002 Jan 12;359(9301):145-9
pubmed: 11809274
Med Decis Making. 2013 Aug;33(6):743-54
pubmed: 23341049
Stat Med. 2005 Jan 15;24(1):131-45
pubmed: 15515137
Stat Med. 1999 Aug 15;18(15):1903-42
pubmed: 10440877
Health Qual Life Outcomes. 2018 Feb 12;16(1):31
pubmed: 29433510
Health Econ Policy Law. 2019 Jan;14(1):119-134
pubmed: 29673412
Value Health. 2019 Aug;22(8):898-905
pubmed: 31426931
Value Health. 2016 Mar-Apr;19(2):125-37
pubmed: 27021745

Auteurs

Matthew Franklin (M)

Health Economics and Decision Science (HEDS), School of Health and Related Research (ScHARR), University of Sheffield, West Court, 1 Mappin Street, Sheffield, S1 4DT, UK. matt.franklin@sheffield.ac.uk.

James Lomas (J)

Centre for Health Economics, University of York, Heslington, York, UK.

Gerry Richardson (G)

Centre for Health Economics, University of York, Heslington, York, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH